Searchable abstracts of presentations at key conferences in endocrinology

ea0077p234 | Reproductive Endocrinology | SFEBES2021

Reproductive health disturbance in the era of the COVID-19 pandemic

Maher Michelle , Keeffe Aedin O’ , Phelan Niamh , Ann Behan Lucy , Collier Sonya , Hevey David , Owens Lisa

Background: The combined effect of the COVID-19 pandemic and associated restrictions have adversely affected population mental health. Periods of psychological distress can induce menstrual dysfunction. We previously demonstrated a significant disruption in women’s reproductive health during the first 6 months of the pandemic. The present study investigates longer term reproductive and mental health disturbances.Materials and Methods: An online surv...

ea0086p120 | Reproductive Endocrinology | SFEBES2022

Female reproductive health disturbance associated with the COVID-19 pandemic persists despite improving mental health- a longitudinal observational study

Lonergan Eibhlin , Maher Michelle , Collier Sonya , Ann Behan Lucy , Phelan Niamh , Hevey David , Owens Lisa

Background: The COVID-19 pandemic has adversely affected population mental health. In April 2021 we conducted an observational study which demonstrated disruption in women’s reproductive and mental health during the first year of the pandemic. Our objective therefore was to perform follow up studies in this cohort of women at 6-monthly intervals, to assess the longer term enduring impact of the pandemic on reproductive and mental health.Materials/Me...

ea0094p258 | Reproductive Endocrinology | SFEBES2023

Significant weight loss associated with GLP1 receptor agonist use in obese women with polycystic ovary syndrome- a retrospective cohort study

Alawami Fatimah , Novaes Olivia , Gibney James , Phelan Niamh , Ann Behan Lucy , Owens Lisa

Introduction: Women with polycystic ovary syndrome (PCOS) have a higher prevalence of obesity and weight gain. Obesity negatively impacts the fertility, mental wellbeing and long term health of women with PCOS. The 2023 international guidelines for the management of PCOS suggest that GLP1 receptor agonists could be considered, but highlight a lack of evidence for medical obesity treatment in women with PCOS. Previous studies showed that interventions which red...

ea0094p351 | Metabolism, Obesity and Diabetes | SFEBES2023

Time-restricted eating in polycystic ovarian syndrome: a randomised crossover feasibility study of real-world clinical advice

Floyd Ruairi , Gibney James , Owens Lisa , Phelan Niamh , Rakovac Ana , Le Roux Carel , Duggan Sinead , Ann Behan Lucy

Objective: Time-restricted eating (TRE) represents a novel intervention that may improve insulinaemia and reduce weight, but is untested in polycystic ovarian syndrome (PCOS). In a randomised interventional study (NCT05126199), we investigated the feasibility of TRE in PCOS. Secondary objectives included effects on insulin and metabolic indices.Methods: Participants were randomised to 12-week TRE (18h fast/6h eating wind...

ea0056p395 | Diabetes (to include epidemiology, pathophysiology) | ECE2018

Hyperandrogenaemia in women with type 1 diabetes mellitus; associations with lipids and lipoprotein particle size, and early vascular disease

Gunness Anjuli , Pazderska Agnieszka , Ahmed Mohamed , McGowan Anne , Phelan Niamh , Boran Gerard , Taylor Angela , O'Reilly Michael , Arlt Wiebke , Moore Kevin , Ann Behan Lucy , Sherlock Mark , Gibney James

Hyperandrogenaemia and polycystic ovary syndrome (PCOS) are common in women with Type 1 diabetes, but it is not known if they contribute to increased cardiovascular risk. We aimed to compare associations between androgen levels, lipid variables and early atherosclerosis in reproductive-age women with and without T1DM. 87 (16 with PCOS) women with T1DM (mean±SD; age 28.7±6.1yrs, BMI 25.4±4.4kg/m2), and 87 (16 PCOS) nondiabetic women (mean±SD; age ...